Bristol-Myers Squibb Company
NYSE: BMY
$59.22
+$0.48 (+0.8%)
Real Time Data Delayed 15 Min.
BMY Articles
ThinkstockBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) had approved the drug ELIQUIS, as a treatment for Deep...
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Tuesday, July 2, 2014. They include Alcatel-Lucent, Apple, FireEye, JDSU Uniphase and solar stocks.
Published:
In a new report, the analysts at health care boutique Leerink highlight numerous upcoming catalysts for some top stocks in the sector. Catalysts may move the stocks sharply either way, depending on...
Published:
These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, June 5, 2014. They include Apple, Lululemon, Microsoft, NBG, Twitter and Whole Foods.
Published:
A new report from the global equity strategy team at Credit Suisse maintains that the best defensive sector now is large cap pharmaceuticals. Here are their top large cap pharmaceuticals to buy now.
Published:
These are the top Wall Street analyst upgrades, downgrades and initiations seen on Thursday, May 15, 2014. They include Cisco Systems, Kinder Morgan, Rackspace, Twitter and L-3 Communications.
Published:
In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off that may provide investors some incredible outsized gains over the rest of the year.
Published:
Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large biotechnology stocks were not the lone...
Published:
In a new research report, Cowen analysts posted a list of some of the top new datapoints cited at the Cowen 2014 Healthcare Conference by large cap pharmaceutical companies concerning upcoming events...
Published:
Cadence Pharmaceuticals agreed Tuesday to be bought out by Mallinckrodt for $1.3 billion, or a more than 27% premium to Monday's closing share price. Some investors may anticipate a sweetened offer.
Published:
Frank Golhen, via Wikimedia CommonsMost of the firms that we cover on Wall Street have presented their high conviction stock picks for 2014. The analysts at Credit Suisse have taken a little bit...
Published:
ThinkstockThe wave of mergers and acquisitions in health care continues with two big announcements Monday. Drug maker Shire PLC (NASDAQ: SHPG) will acquire the rare disease biopharmaceutical company...
Published:
Jon OggEarnings season is in full swing and equities are challenging new highs almost daily. Traders and investors are looking for stocks to buy and for ideas on which stocks to sell. 24/7 Wall St....
Published:
ThinkstockThe drug and pharmaceutical sector is supposed to be a defensive one by nature, even if this week’s government shutdown and impending debt ceiling weighed heavily on biotech stocks....
Published:
ThinkstockAs the pharmaceuticals industry looks toward restructuring and separation of undervalued assets, Jefferies analysts have prepared a highly proprietary sum of the parts analysis for their...
Published:
Last Updated: